[ad_1]
KATY, TX / ACCESSWIRE / September 13, 2021 / Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent (LOI) with a Houston medical analysis firm that, if it involves a profitable conclusion, would result in testing hemp-based cannabinoids to deal with COVID-19.
Underneath the LOI’s provisions, VIVIS will now decide the feasibility of working with Mercury Medical Analysis to start out section 1 medical trial on CBD efficacies in combating SARS-COVID-2. The trials may additionally examine extra makes use of for anti-inflammation, anti-insomnia, urge for food suppressant and stimulant (CBG vs. CBN), restoration, pain-management, anti-anxiety, and different well being associated analysis deemed notable for medical trials.
‘We’re about to embark on one thing that might have an incredible affect worldwide,’ stated Neutra CEO Sydney Jim. ‘If we finally determine to pursue this medical analysis, it will simply be one of many greatest and extra essential issues we have accomplished. Proper now, COVID has the world in its grip. It is had a far-reaching adverse impact on not solely folks’s well being however has additionally taken a horrible toll on the worldwide financial system. We’ll be whether or not hemp-based CBD like that VIVIS produces may assist reverse that.’
There has already been some examine into the topic. A bunch of medical researchers recently reported that ‘cannabidiol has potential to stop and inhibit SARS-CoV-2 an infection.’ The researchers’ summary states that human sufferers beforehand taking CBD had ‘considerably decrease SARS-CoV-2 an infection incidence’ when in comparison with the overall inhabitants. Click here for more information with this study
Practically 4.6 million people worldwide have died from COVID-19 as of Sep. 7, 2021. Greater than 664,000 of these fatalities have been within the U.S. Nearly two-thirds of Americans (206 million) have gotten not less than one vaccination dose. Nonetheless, new variations of the coronavirus have appeared, threatening progress in combating the sickness and resulting in new infections.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage analysis and improvement firm with a deal with bringing fashionable wholesome residing options to a multibillion-dollar market. Chopping-edge applied sciences throughout the nutraceuticals, meals, and drug, and environmental purification sectors are creating a brand new sort of world culture-one the place during which shoppers are demanding entry to merchandise that promote well being and stave off potential well being risks. One of many nutraceutical sub-markets is the brand new thriving hemp-based CBD market, during which the Firm intends to take part. For extra data, go to the Firm’s web site at http://www.NeutraInc.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Secure Harbor Assertion underneath the Non-public Securities Litigation Reform Act of 1995: This information launch comprises forward-looking data throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended, together with statements that embrace the phrases ‘believes,’ ‘expects,’ ‘anticipate’ or related expressions. Such forward-looking statements contain identified and unknown dangers, uncertainties, and different elements that will trigger the precise outcomes, efficiency, or achievements of the corporate to vary materially from these expressed or implied by such forward-looking statements.
Neutra Contact:
Sydney Jim
888-433-4033
info@neutrainc.com
SOURCE: Neutra Corp
View supply model on accesswire.com:
https://www.accesswire.com/663687/Latest-VIVIS-LOI-Potential-First-Step-to-Phase-1-Clinical-Trial-on-Preventing-COVID-19-Infections-Using-CBD
[ad_2]
Source link